Skip to main content
AAN.com
Brief Communications
February 27, 2006

Course of disability and respiratory function in untreated late-onset Pompe disease

February 28, 2006 issue
66 (4) 581-583

Abstract

Fifty-two untreated patients with late-onset Pompe disease completed questionnaires about their clinical condition and level of handicap at baseline and at 1-year (n = 41) and 2-year follow-ups (n = 40). During this period, declines in functional activities, respiratory function, handicap, and survival were recorded on a group level. This study illustrates the progressiveness of late-onset Pompe disease and indicates the need for close clinical follow-up of both children and adults with this disorder.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Hirschhorn R, Reuser AJJ. Glycogen storage disease type II; acid α-glucosidase (acid maltase) deficiency. In: Scriver, CR, Beaudet A, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw-Hill, 2001:3389–3420.
2.
Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356:397–398.
3.
Winkel LP, Van den Hout JM, Kamphoven JH, et al. Enzyme replacement therapy in late-onset Pompe’s disease: a three-year follow-up. Ann Neurol 2004;55:495–502.
4.
Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005;15:24–31.
5.
Ausems MGEM, Verbiest J, Hermans MMP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 1999;7:713–716.
6.
Van den Hout JMP, Hop W, Van Diggelen OP, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332–340.
7.
Hagemans ML, Winkel LP, Van Doorn PA, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain 2005;128 (pt 3):671–677.
8.
Hagemans ML, Winkel LP, Hop WC, Reuser AJ, Van Doorn PA, Van der Ploeg AT. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 2005;64:2139–2141.
9.
Merkies IS, Schmitz PI, Van der Meche FG, Samijn JP, Van Doorn PA. Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve 2002;25:370–377.
10.
Makos MM, McComb RD, Hart MN, Bennett DR. Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship. Ann Neurol 1987;22:629–633.

Information & Authors

Information

Published In

Neurology®
Volume 66Number 4February 28, 2006
Pages: 581-583
PubMed: 16505317

Publication History

Published online: February 27, 2006
Published in print: February 28, 2006

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

M.L.C. Hagemans, MSc
From the Department of Metabolic Diseases and Genetics (M.L.C.H., A.T.V.d.P.), Erasmus MC-Sophia, Rotterdam; and the Department of Epidemiology and Biostatistics (W.J.C.H.), Department of Neurology (P.A.V.D.), and Department of Clinical Genetics (M.L.C.H., A.J.J.R.), Erasmus MC, Rotterdam, The Netherlands.
W. J.C. Hop, PhD
From the Department of Metabolic Diseases and Genetics (M.L.C.H., A.T.V.d.P.), Erasmus MC-Sophia, Rotterdam; and the Department of Epidemiology and Biostatistics (W.J.C.H.), Department of Neurology (P.A.V.D.), and Department of Clinical Genetics (M.L.C.H., A.J.J.R.), Erasmus MC, Rotterdam, The Netherlands.
P. A. Van Doorn, MD, PhD
From the Department of Metabolic Diseases and Genetics (M.L.C.H., A.T.V.d.P.), Erasmus MC-Sophia, Rotterdam; and the Department of Epidemiology and Biostatistics (W.J.C.H.), Department of Neurology (P.A.V.D.), and Department of Clinical Genetics (M.L.C.H., A.J.J.R.), Erasmus MC, Rotterdam, The Netherlands.
A. J.J. Reuser, PhD
From the Department of Metabolic Diseases and Genetics (M.L.C.H., A.T.V.d.P.), Erasmus MC-Sophia, Rotterdam; and the Department of Epidemiology and Biostatistics (W.J.C.H.), Department of Neurology (P.A.V.D.), and Department of Clinical Genetics (M.L.C.H., A.J.J.R.), Erasmus MC, Rotterdam, The Netherlands.
A. T. Van der Ploeg, MD, PhD
From the Department of Metabolic Diseases and Genetics (M.L.C.H., A.T.V.d.P.), Erasmus MC-Sophia, Rotterdam; and the Department of Epidemiology and Biostatistics (W.J.C.H.), Department of Neurology (P.A.V.D.), and Department of Clinical Genetics (M.L.C.H., A.J.J.R.), Erasmus MC, Rotterdam, The Netherlands.

Notes

Address correspondence and reprint requests to A.T. van der Ploeg, MD, PhD, Erasmus MC-Sophia, Sp 2435, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands; e-mail:[email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Respiratory considerations in patients with neuromuscular disorders, Muscle & Nerve, 68, 2, (122-141), (2023).https://doi.org/10.1002/mus.27845
    Crossref
  2. Is the brain involved in patients with late‐onset Pompe disease?, Journal of Inherited Metabolic Disease, 45, 3, (493-501), (2022).https://doi.org/10.1002/jimd.12469
    Crossref
  3. The late-onset form of Pompe disease, Neurologie pro praxi, 22, 4, (325-330), (2021).https://doi.org/10.36290/neu.2021.053
    Crossref
  4. Treatable lysosomal storage diseases in the advent of disease‐specific therapy, Internal Medicine Journal, 50, S4, (5-27), (2020).https://doi.org/10.1111/imj.15100
    Crossref
  5. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state‐of‐the art review, The Clinical Respiratory Journal, 14, 5, (422-429), (2020).https://doi.org/10.1111/crj.13150
    Crossref
  6. Body composition and 6 minute walking ability in late-onset pompe disease patients after 9 years of enzyme replacement therapy, International Journal of Neuroscience, 132, 7, (699-705), (2020).https://doi.org/10.1080/00207454.2020.1835902
    Crossref
  7. Utility of maximum inspiratory and expiratory pressures as a screening method for respiratory insufficiency in slowly progressive neuromuscular disorders, Neuromuscular Disorders, 30, 8, (640-648), (2020).https://doi.org/10.1016/j.nmd.2020.06.009
    Crossref
  8. Hereditary Neuromuscular Diseases and Cardiac Involvement, Clinical Cardiogenetics, (371-385), (2020).https://doi.org/10.1007/978-3-030-45457-9_22
    Crossref
  9. The nature of respiratory muscle weakness in patients with late-onset Pompe disease, Neuromuscular Disorders, 29, 8, (618-627), (2019).https://doi.org/10.1016/j.nmd.2019.06.011
    Crossref
  10. Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease, Acta Neuropathologica Communications, 6, 1, (2018).https://doi.org/10.1186/s40478-018-0620-3
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share